MoonLake Immunotherapeutics (MLTX)
45.23
+2.80
(+6.60%)
USD |
NASDAQ |
May 03, 16:00
45.23
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics Cash from Operations (TTM): -42.78M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -42.78M |
September 30, 2023 | -42.03M |
June 30, 2023 | -42.13M |
Date | Value |
---|---|
March 31, 2023 | -50.73M |
December 31, 2022 | -55.89M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-55.89M
Minimum
Dec 2022
-42.03M
Maximum
Sep 2023
-46.71M
Average
-42.78M
Median
Dec 2023
Cash from Operations (TTM) Benchmarks
Qiagen NV | 520.61M |
LENZ Therapeutics Inc | -- |
AC Immune SA | -67.27M |
CRISPR Therapeutics AG | -260.38M |
Addex Therapeutics Ltd | -8.901M |